Global and Local Pharmacovigilance Services, since 2008

Sam Tomlinson appointed as
VP of Global Drug Safety.

Missing image

Sam has over 20 years strategic and operational experience and will develop and direct our clinical and non-clinical pharmacovigilance services and solutions.

We are happy to announce that Sam Tomlinson has joined Arriello to develop and direct our clinical and non-clinical pharmacovigilance services and solutions, and lead our expanding multi-national PV team.

She has over 20 years strategic and operational experience in global Pharmacovigilance in both large pharma and small to medium sized pharma organizations.

Sam started her Pharmacovigilance career working at Eli Lilly and has gone on to lead global pharmacovigilance teams working across a broad range of therapeutic areas, most recently working with specialty pharma building safety and risk management systems.

Sam also has experience as an EU QPPV and her expertise spans across the product lifecycle from clinical trials, through post marketing and product discontinuation.

Additionally, she has managed and supported numerous Health Authority inspections including EMA, FDA, MHRA, ANSM, Health Canada, HPRA, and AIFA.

Sam will report to Arriello’s COO Anna Lukyanova.

Latest News

The benefits of using Veeva Vault Safety, for us, it means that we are able to use their reporting capabilities directly from the safety database. We are able to use the gateway connection with the regulatory authorities and with partners.
Arriello modernizes pharmacovigilance with Veeva Vault Safety.
Kieran and Nicola speaking about our latest US/UK/EU survey which provides initial feedback from senior PV and Reg professionals across 4 countries on the EMA’s new Clinical Trials Regulation (CTR) that will be fully applicable from January 31 2023.
BIO Europe 2022: Fireside chat about CTR/CTIS.
Peter Embley joins Arriello to lead it’s Regulatory Affairs team and comes with over 24 years of experience working across the Pharmaceutical, CRO and Consulting Industries.
Peter Embley appointed as Chief Regulatory Officer.